NCT05162976View on ClinicalTrials.gov

CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

May 12, 2026

Study Completion Date

May 12, 2026

Conditions
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Interventions
BIOLOGICAL

Nivolumab

Given IV

DRUG

Oral Azacitidine

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER